Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor de veloped by Merck. In October 2006, Sitagliptin phosphate Januvia was approved" by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus.↔ The characteristics of this drug are that it can stimulate insulin secretion$ while reducing hunger without causing weight gain. Hypogly¥cemia and edema will not occur, and it is suitable for diabetic patients with poor ≈blood glucose control and frequent hypoglycemia.

key word:

hypoglycemia treatment stimulate

Category:

Consulting

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health i♣ndustry finance platform company integrating pharmaceutical, intelligent medical, bio phδarmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction,δ nitration reaction, sulfonation reaction, hydrogenation react≈ion, fluorination reaction, chlorination reaction, bromination÷ reaction, diazotization reaction, format reaction, etc.

Blockbuster drug for type 2 diabetes

It is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In October 2006, Sitaglipt in phosphate Januvia was approved by FDA as the first DPP4 inhibitor f✔or the treatment of type ⅱ diabetes mellitus. The characteristics of this drug are that$ it can stimulate insulin secretion while reducing hunger without causing weight gain. Hypoglycemia→ and edema will not occur, and it is suitable for diabetic patients wi∞th poor blood glucose control and frequent hypoglycemia. By inhibiting the ac✔tivity of this enzyme, the drug can relatively increase→ the levels of naturally occurring incretin, including glucagon-like 'peptide-1 and glucose-dependent insulin-stimulating peptide, thereby trig gering the clinical effect of increasing insulin production in the✔ pancreas and stopping glucose production in the liver, ultim♥ately lowering blood glucose concentration. The DRUG H✔AS A PROMISING MARKET, WITH SALES OF sitaglipTIN PHOSPHATE REACHING $185 MILLION IN THE THIRD quεarter OF 2007 alone. Peak sales of sitagliptin are forecast to reach $1 billion by± 2010. $3.306 billion in 2020, combined with metformin¶ in 2020 sales of $1.971 billion.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Mer​ck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibi↕tor for the treatment of type ⅱ diabetes mellitus. The charact→eristics of this drug are that it can stimulate insulin secre≤tion while reducing hunger without causing weight gain. Hypoglycem•ia and edema will not occur, and it is suitable for diabetic patients  with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharma>ceutical enterprise that is market-oriented and rea™lizes industrial development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for t§he treatment of arthritis. It is well tolerated and has a low incidence of si♣de effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor ≤antagonists. In clinical application, it has good therapeutic $effect on atopic asthma and other types of bronchial asthma, and ¶the market prospect is huge. In the major category of asthma drugs, leuk¥otriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmace∏utical enterprise that is market-oriented and realizes ¥industrial development through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved b↑y FDA for Alzheimer's disease in the United States.' Its treatment reaches the target dose and has low toxic and side effects. It ha"s been widely recognized by our medical community, and good tolerance is its biggest advantage.™ In October 1999, Donepezil was launched in China under the ©trade name "Aricept", which is the main chemical drug against Alzheimer's disease. At present, CFD₽A has approved a number of domestic enterprises to produce donepeziδl preparations, the main dosage forms are tablets, capsu$les, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer©), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. The worlβd's first drug approved to prevent venous thromboembolism (VT↕E) in adult patients undergoing elective hip or knee replacement. From June 2019 to June 2020,λ the annual sales of apixaban products overseas reached about $15.4 billion, with a year-on×-year growth of nearly 32%, and the API consumption₩ reached about 23,960 kg, with a year-on-year growth of about 28%. ™Compared with its main competitor, Rivaroxaban, the drug's annual overse★as sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech ≈pharmaceutical enterprise that is market-oriented and realizes industrial devel™opment through R&D innovation and technology transforma tion.

Clofarabine

It is a nucleotide analogue developed by Bioenvisiγon and manufactured by Genzyme. On December 29, 2004, it was a✘pproved by FDA for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in ≥children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-←oriented and realizes industrial development through R&D innovation and technology tra$nsformation.

Product Consulting

Our staff will contact you within 24 hours (working days).™ If you need other services, E-mail: 2880705932@qq.com